SCHEMBL21176247

SCHEMBL21176247

CC(C(=O)C(=O)NCC1CC1)N(C=O)CC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
TGFBR1 P36897 3/20 0.38
GPR119 Q8TDV5 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LIMK2 P53671 1/20 0.37
EPHX1 P07099 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
GLS O94925 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176384 0.95 KDM4E (0.46) KDM4EPKMFPR3FPR2SMN1; SMN2
SCHEMBL21176196 0.84 KDM4E (0.47) KDM4EPKMFPR3FPR2SMN1; SMN2
SCHEMBL21183545 0.83 KDM4E (0.45) KDM4EPKMFPR3FPR2SMN1; SMN2
SCHEMBL19974790 0.80 SIGMAR1 (0.40) KDM4ESMN1; SMN2ALDH1A1EPHX1HPGD
SCHEMBL21183548 0.80 EPHX2 (0.39) KDM4ESMN1; SMN2ALDH1A1L3MBTL1EPHX1
SCHEMBL19974880 0.80 ALDH1A1 (0.35) KDM4ESMN1; SMN2ALDH1A1L3MBTL1EPHX1
SCHEMBL21176200 0.79 KDM4E (0.45) KDM4EPKMFPR3FPR2SMN1; SMN2
SCHEMBL19975075 0.79 USP2 (0.38) KDM4ESMN1; SMN2ALDH1A1MAPK1L3MBTL1
SCHEMBL19975106 0.78 EPHX1 (0.40) SMN1; SMN2NPC1ALDH1A1RAB9AL3MBTL1
SCHEMBL19975427 0.78 EPHX1 (0.47) KDM4EPKMSMN1; SMN2ALDH1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KDM4E 3330/4885PKM 2897/4885FPR3 1024/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KDM4E 3784/4885PKM 3299/4885FPR3 1235/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KDM4E 3330/4885PKM 2897/4885FPR3 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.